A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
OHSU Knight Cancer Institute
National Cancer Institute (NCI)
Revolution Medicines, Inc.
Seagen Inc.
Pfizer
City of Hope Medical Center
Novartis
Medicine Invention Design, Inc
Amal Therapeutics